Simple Summary Acquired resistance to chemotherapy by cancer cells is the predominant
factor in chemotherapy failure, which ultimately leads to disease progression and death …

The goals of the Association for Molecular Pathology (AMP) Clinical Practice Committee's
Pharmacogenomics (PGx) Working Group are to define the key attributes of …

The purpose of this guideline is to provide information for the interpretation of clinical
dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to …

5-Fluorouracil remains a foundational component of chemotherapy for solid tumour
malignancies. While considered a generally safe and effective chemotherapeutic, 5 …

Simple Summary 5-Fluorouracil (5-FU) is a chemotherapy drug that is commonly used to
treat multiple cancers. Many people who are treated with 5-FU experience severe toxicity to …

PURPOSE Patients who carry pathogenic variants in DPYD have higher systemic
fluoropyrimidine (FP) concentrations and greater risk of severe and fatal FP toxicity …

Fluoropyrimidines (FPs), mainly 5-fluorouracil (5-FU) and its oral prodrug capecitabine
(Cap), remain the backbone of the treatment of many different solid tumors. Despite their …

Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the
treatment of cancer, especially gastrointestinal tumors and breast cancer, but their …

Fluoropyrimidine drugs (FP) are the backbone of many chemotherapy protocols for treating
solid tumours. The rate-limiting step of fluoropyrimidine catabolism is dihydropyrimidine …

Background Dihydropyrimidine dehydrogenase (DPD) deficiency is the main known cause
of life-threatening fluoropyrimidine (FP)-induced toxicities. We conducted a meta-analysis on …